Global Kidney Cancer Drugs Market Research Report 2023: Forecasts to 2027 & 2032 with Focus on Axitinib (Inlyta), Cabozantinib (cabometyx), and Pazopanib
March 13, 2023 08:53 ET
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global kidney cancer drugs market will...
Global Kidney Cancer Drugs Market Report 2022-2026 & 2030 - Focus on Immunotherapy, Chemotherapy and Targeted Therapy
April 19, 2022 04:48 ET
|
Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2022, Type, Product, End Users" report has been added to ResearchAndMarkets.com's offering. The global...
Kidney Cancer Drugs Industry Assessment and Recovery to 2030 - Insights on Drugs, Trends, Global Market Shares, Competitors, Strategies and More
February 04, 2022 04:38 ET
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
November 01, 2021 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Global Kidney Cancer Diagnostics and Therapeutics Market (2020 to 2026) - Featuring Abbvie, Active Biotech and AstraZeneca Among Others
August 05, 2021 07:53 ET
|
Research and Markets
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Kidney Cancer Diagnostics and Therapeutics Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global kidney...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
March 09, 2021 07:30 ET
|
Graybug Vision, Inc.
Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
March 04, 2021 17:04 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision to Participate in SVB Leerink Global Healthcare Conference
February 17, 2021 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
February 01, 2021 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021
January 07, 2021 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...